Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.6822
+0.0412 (6.43%)
At close: Oct 8, 2025, 4:00 PM EDT
0.6775
-0.0047 (-0.69%)
After-hours: Oct 8, 2025, 7:56 PM EDT
Virax Biolabs Group Employees
Virax Biolabs Group had 19 employees as of March 31, 2025. The number of employees increased by 2 or 11.76% compared to the previous year.
Employees
19
Change (1Y)
2
Growth (1Y)
11.76%
Revenue / Employee
$333
Profits / Employee
-$319,013
Market Cap
2.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19 | 2 | 11.76% |
| Mar 31, 2024 | 17 | 6 | 54.55% |
| Mar 31, 2023 | 11 | 6 | 120.00% |
| Mar 31, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VRAX News
- 6 weeks ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire
- 2 months ago - Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy - PRNewsWire
- 2 months ago - Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - PRNewsWire
- 6 months ago - Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga
- 7 months ago - Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes - PRNewsWire
- 7 months ago - Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting - PRNewsWire
- 7 months ago - Virax Biolabs to Present at 19th World Immune Regulation Meeting - PRNewsWire
- 8 months ago - Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy - PRNewsWire